AI Article Synopsis
- Inflammation is a key factor in many chronic diseases, and silibinin has strong anti-inflammatory properties but low effectiveness in the body due to poor absorption.
- This study examines how dibenzoylmethane (DBM) can enhance silibinin's effects, revealing that their combination significantly reduces inflammatory markers in both cell and animal models.
- The findings suggest that DBM and silibinin work together by targeting specific signaling pathways and proteins, making their combination a promising strategy for improving anti-inflammatory treatments.
Article Abstract
Inflammation is an important predisposing factor for many chronic diseases. The dietary flavonoid silibinin has excellent anti-inflammatory properties in cells, but its low bioavailability in the blood compromises its therapeutic potential. This study aims to investigate the potential of dibenzoylmethane (DBM) to synergistically enhance the anti-inflammatory benefits of silibinin (SB). The synergistic effects of DBM and SB in combination were evaluated in LPS-induced RAW264.7 cells and TPA-induced mice. In addition, a network pharmacology approach and molecular docking were used to explore the key targets and signaling pathways of DBM and SB in combination. The results showed that DBM and SB synergistically inhibited the production of NO, ROS, IL-1β, and TNF-α in a 1:1 concentration ratio. These two compounds may exert their synergistic effects by modulating the NF-κB and HIF-1 signaling pathways, among others. Molecular docking revealed that both compounds exhibited high binding affinities to iNOS and COX-2. Compared with single compound use, the two compounds in combination significantly reduced ear edema and inflammatory cell infiltration, and inhibited the protein expression of iNOS and COX-2 in TPA-induced mice. This research provides a rationale for the combination of DBM and SB as an effective anti-inflammatory agent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cbdv.202402567 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Inflammation is a key factor in many chronic diseases, and silibinin has strong anti-inflammatory properties but low effectiveness in the body due to poor absorption.
- This study examines how dibenzoylmethane (DBM) can enhance silibinin's effects, revealing that their combination significantly reduces inflammatory markers in both cell and animal models.
- The findings suggest that DBM and silibinin work together by targeting specific signaling pathways and proteins, making their combination a promising strategy for improving anti-inflammatory treatments.
Chlorogenic acid suppresses the expression of matrix metalloproteinase-7 and cell invasiveness to almost the same extent as isofraxidin in human colorectal cancer cells.
In Vitro Cell Dev Biol Anim
December 2024
The Third Hospital, Kohno Clinical Medicine Research Institute, 3-4-4 Kita-Shinagawa, Shinagawa-Ku, Tokyo, 140-0001, Japan.
The expression of matrix metalloproteinase (MMP)-7 is reported to be correlated with invasion and metastasis of colorectal cancer (CRC). Therefore, the inhibition of MMP-7 would be beneficial for the suppression or prevention of CRC cell invasion and metastasis. The stem bark of Acanthopanax senticosus, a widely used medicinal herb, contains isofraxidin (IF) and chlorogenic acid (CGA) as major components.
View Article and Find Full Text PDFAnti-Inflammatory Effects of Extracellular Vesicles from on 12-O-Tetradecanoylphorbol-13-Acetate-Induced Skin Inflammation in Mice.
Int J Mol Sci
November 2024
Functional Cellular Networks Laboratory, Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon 21999, Republic of Korea.
Steroids, which are often used to treat the inflammation associated with various skin diseases, have several negative side effects. As extract has anti-inflammatory effects in various diseases, we evaluated the efficacy of -derived extracellular vesicles (EVEs) in decreasing 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation. We determined the effect of the EVEs on the TLR4/NF-κB/NLRP3 inflammasome in human keratinocytes and mouse ear skin.
View Article and Find Full Text PDFUnveiling the chemotherapeutic potential of two platinum(IV) complexes in skin cancer: Insights.
Curr Res Pharmacol Drug Discov
October 2024
School of Arts and Sciences, Department of Natural Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Article Synopsis
- The study evaluates two platinum (IV) complexes, P-PENT and P-HEX, for their effectiveness against skin cancer, showing strong cytotoxic effects on HaCaT-II-4 cells while being less harmful to mesenchymal stem cells.
- The complexes trigger intrinsic apoptosis through key biochemical pathways, increasing apoptotic markers and reactive oxygen species, suggesting they induce cancer cell death.
- In a mouse model, both complexes significantly inhibited tumor growth with lower doses than those used for traditional treatments like cisplatin, indicating they might be safer and more effective options for skin cancer therapy.
Disabled 2 (Dab2) Regulates Tumour Progression in Skin Squamous Cell Carcinoma.
Exp Dermatol
November 2024
Stem Cell Biology Group, Waghmare Lab, Cancer Research Institute, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Dab2 is an endocytic adaptor protein involved in various physiological processes and signaling pathways. Dab2 is deregulated in various cancers; however, its role in skin squamous cell carcinoma ( SCC) has not been elucidated yet. In the present study, we used the DMBA/TPA induced murine skin carcinogenesis model to examine the role of Dab2 in skin tumour progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!